重酒石酸卡巴拉汀胶囊联合司来吉兰对帕金森病的治疗价值研究

摘要/Abstract

摘要： 目的研究重酒石酸卡巴拉汀胶囊联合司来吉兰在帕金森病患者身上的治疗价值。方法选取2020年10月~2021年9月前郭尔罗斯蒙古族自治县医院收治的80例帕金森病患者作为研究对象,根据随机数表法分为对照组和研究组,每组40例。对照组患者给予司来吉兰治疗,研究组患者给予重酒石酸卡巴拉汀胶囊联合司来吉兰治疗,比较两组患者治疗后的治疗效果、不良反应、IGF-1（胰岛素生长因子）与Aβ1-42（人β–淀粉样多肽 1-42）、生活质量、认知功能、帕金森病综合评分。结果治疗后,研究组患者IGF-1与Aβ1-42高于对照组,差异有统计学意义（P<0.05）;两组患者不良反应发生率比较,差异无统计学意义（P>0.05）;研究组患者治疗效果高于对照组,差异有统计学意义（P<0.05）。治疗后,研究组患者SF-36评分高于对照组,差异有统计学意义（P<0.05）;研究组患者的认知功能高于对照组,差异有统计学意义（P<0.05）;治疗前,研究组患者帕金森病综合评分与对照组患者比较,差异无统计学意义（P>0.05）;治疗后,研究组患者帕金森病综合评分低于对照组,差异有统计学意义（P<0.05）。结论重酒石酸卡巴拉汀胶囊联合司来吉兰治疗帕金森病,可以调整患者相关血清学指标,改善患者生活质量以及认知功能,提高治疗效果,值得临床应用。

关键词: 重酒石酸卡巴拉汀胶囊, 司来吉兰, 帕金森病, 认知功能, 生活质量

Abstract: Objective To explore the value of the treatment and application of rivastigmine bitartrate capsules combined with selegiline in the treatment of Parkinson’s disease. Methods A total of 80 patients with Parkinson’s disease who were admitted to the Department of Neurology of Goerroth Mongolian Autonomous County Hospital from October 2020 to September 2021 were selected as the research subjects. According to the random number table method, they were divided into control group and study group, with 40 patients in each group. Control group was given selegiline treatment, study group was given carbalatin ditartrate capsule combined selegiline treatment, treatment effect, adverse reactions, IGF-1 （insulin growth factor） and Aβ1-42 （human β -amyloid polypeptide 1-42）, quality of life, cognitive function after treatment,score of Parkinson’s disease in 2 groups were compared. Results After treatment, IGF-1 and Aβ1-42 in study group were higher than those in control group, and the difference was statistically significant （P<0.05）. There was no significant difference in the incidence of adverse reactions between 2 groups （P>0.05）. The therapeutic effect of the study group was higher than that of the control group, and the difference was statistically significant （P<0.05）. After treatment, the SF-36 score of patients in the study group was higher than that in the control group, the difference was statistically significant （P<0.05）; The cognitive function of the study group was higher than that of the control group, and the difference was statistically significant （P<0.05）. Before treatment, there was no significant difference in the comprehensive score of Parkinson’s disease between study group and control group （P>0.05）. After treatment, the comprehensive score of Parkinson’s disease in study group was lower than that in control group, and the difference was statistically significant （P<0.05）. Conclusion Rivastigmine Bitartrate Capsules combined with selegiline in the treatment of Parkinson’s disease can acan adjust the relevant serological indicators of patients, improve the quality of life and cognitive function of patients, improve the therapeutic effect, worthy of clinical application.

Key words: Rivastigmine bitartrate capsules, selegiline, parkinson's disease, cognitive function, quality of life

中图分类号:

R741

王安影, 吕殿平. 重酒石酸卡巴拉汀胶囊联合司来吉兰对帕金森病的治疗价值研究[J]. 中华养生保健, 2022, 40(13): 8-11.

WANG An-ying, LU Dian-ping. Observation on the Therapeutic Value of Rivastigmine Bitartrate Capsules Combined with Selegiline in the Treatment of Parkinson’s Disease[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(13): 8-11.

参考文献

[1] 苏娜,吴斌,徐珽.司来吉兰治疗帕金森病的有效性与安全性的系统评价[J].中国医院药学杂志,2019,34(14):1206-1212.
[2] 叶虹,罗丽霞,李飞,等.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察[J].中国医药导报,2018,11(28):58-61.
[3] 刘军. 中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016, 49(4):268-271.
[4] 杨丽娟,牛晓珊,何晓燕,等.多巴胺受体激动剂普拉克索和单胺氧化酶B抑制剂司来吉兰治疗早期帕金森综合征的疗效对比[J].中华脑科疾病与康复杂志,2018,8(1):20-24.
[5] 程政平,吴琼,李学锋,等.帕金森病应用美多芭联合盐酸司来吉兰治疗的效果探究[J].中国现代药物应用,2018,12(1):125-126.
[6] 赵轶,席刚明.盐酸多奈哌齐片联合司来吉兰片对帕金森病患者认知功能及智力状态的影响[J].贵州医药,2018,42(3):312-314.
[7] 汤春琼. 司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床效果探析[J].中国现代药物应用,2018,12(23):78-79.
[8] 潘可达,陈为安,方慧,等.盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床研究[J].中国临床药理学杂志,2017,33(8):690-693.
[9] 曲艳,李晓红.司来吉兰与雷沙吉兰治疗帕金森病的有效性和安全性对比[J].中国现代药物应用,2019,13(24):204-205.
[10] 刘艳玲,罗永煌,田朋鑫,等.反相HPLC法测定重酒石酸卡巴拉汀胶囊的含量及有关物质[J].药物分析杂志,2011,31(4):721-724.
[11] 陈中华. 重酒石酸卡巴拉汀胶囊联合经颅磁刺激治疗脑卒中后认知功能障碍的疗效观察[J].临床医学工程,2020,27(7):925-926.
[12] 方圆,李晓晖.卡巴拉汀联合司来吉兰治疗帕金森病的效果及对血清Aβ1-42,IGF-1水平的影响[J].中国实用医刊,2021,48(17):101-104.
[13] 冯帅南. 帕金森病患者应用司来吉兰联合多奈哌齐治疗对其血清SOD,MDA,GSH水平的影响[J].现代诊断与治疗,2020,31(5):681-683.

[1]	雷婷, 薛琳. 平衡运动训练联合认知刺激治疗对脑卒中偏瘫患者平衡能力、认知及下肢功能的影响[J]. 中华养生保健, 2024, 42(9): 68-71.
[2]	何育红, 文小艳. 中医定向透药联合音乐护理对冠心病患者负面情绪及生活质量影响[J]. 中华养生保健, 2024, 42(9): 109-112.
[3]	杨海娜. 心理干预联合健康宣教对冠心病心绞痛患者治疗依从性、生活质量影响[J]. 中华养生保健, 2024, 42(9): 119-121.
[4]	温海燕. 思维导图下的分阶段家庭访视护理对老年高血压患者QOL评分、MCMQ评分的影响[J]. 中华养生保健, 2024, 42(9): 144-147.
[5]	吕晓珊, 马晓睿. 认知干预联合SBAR沟通对妊娠高血压患者生活质量及负面情绪的影响[J]. 中华养生保健, 2024, 42(9): 150-153.
[6]	钟金侠. CICARE沟通方式对CHD患者经皮冠状动脉介入治疗后疾病不确定感、自我护理能力及生活质量的影响[J]. 中华养生保健, 2024, 42(8): 106-109.
[7]	陈美玲. 聚焦解决护理模式对结肠癌术后化疗患者癌因性疲乏和生活质量的影响[J]. 中华养生保健, 2024, 42(8): 134-137.
[8]	张艳清. 微信延续性护理联合院内精细化护理对急性心肌梗死患者生活质量的影响[J]. 中华养生保健, 2024, 42(8): 143-146.
[9]	杨欢, 周娟. 基于FTS的多模式护理联合心理干预对胃肠手术患者心理状态及康复效果的影响[J]. 中华养生保健, 2024, 42(8): 156-160.
[10]	秦倩, 张崇海. 红蓝光与粉刺挤压联合果酸换肤治疗中重度痤疮效果对比[J]. 中华养生保健, 2024, 42(8): 181-184.
[11]	胡蓉蓉. 普拉克索联合左旋多巴对帕金森病患者血清Hcy表达与肌张力的影响[J]. 中华养生保健, 2024, 42(7): 13-15.
[12]	王晓雯. 5A+5R护理模式结合渐进式饮食管理对消化性胃溃疡患者的影响[J]. 中华养生保健, 2024, 42(7): 81-84.
[13]	吕彦颖. 医护一体化查房结合AIDET沟通模式对经皮冠状动脉介入治疗患者康复及生活质量影响的研究[J]. 中华养生保健, 2024, 42(7): 90-93.
[14]	吴玉梅. 医护一体化快速康复外科护理对胸腔镜肺癌根治患者术后恢复的影响[J]. 中华养生保健, 2024, 42(7): 111-115.
[15]	张艳波. 早期预警护理干预在心力衰竭患者中的应用效果观察[J]. 中华养生保健, 2024, 42(7): 124-127.